Multiple T-cell surface glycoproteins

Multiple T-cell surface glycoproteins refers to a broad array of antigenic proteins expressed on T-lymphocytes, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, and HLA molecules (Mohty, 2007, Leukemia). These glycoproteins are essential for T-cell maturation, activation, and signaling within the immune system (DrugBank, DB00033). In a therapeutic context, this collective target is addressed by polyclonal antibodies such as Antithymocyte Globulin (ATG), which are used to induce profound immunosuppression (StatPearls, Antithymocyte Globulin). By binding to these various surface markers, drugs promote the depletion of T-cells through mechanisms like complement-mediated lysis, antibody-dependent cellular cytotoxicity, and apoptosis (Mohty, 2007). This approach is primarily utilized in the prevention and treatment of acute organ transplant rejection and graft-versus-host disease (GVHD). However, the broad targeting of T-cells carries significant risks, including cytokine release syndrome, severe lymphopenia, and increased susceptibility to opportunistic infections (StatPearls, Antithymocyte Globulin). The use of these agents requires careful monitoring of lymphocyte counts to ensure efficacy and minimize toxicity.

Other names

T-cell antigensT-lymphocyte surface antigensThymocyte antigens

Polyclonal antibody-mediated depletion of T-cells through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis (Mohty, 2007).